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Viral infections and resulting pandemics 
are a human danger and repeatedly get 
into the focus due to the circulation of 
newly emerging viruses, such as Zika, 
influenza, and corona viruses[1–3] The 
development of antivirals to fight viral 
infections is often a time-consuming pro-
cess and the generated drugs are often 
effective only for a certain period of time 
as mutation of the targeted virus may 
cause the developed antiviral to become 
ineffective, for example due to occur-
rence of resistance.[4] Hence, antivirals 
targeting highly conserved structures of 
viruses, such as the envelope proteins that 
are involved in virus binding to the mem-
brane of the host cell, are entering more 
and more the focus of current research.[5,6] 
As virus binding proteins typically show 
a very weak affinity to their native attach-
ment factors on the cell membrane,[7] 
viruses bind to cells by forming many 
protein-receptor interactions in parallel, 
Multivalent binding inhibitors are a promising new class of antivirals that 
prevent virus infections by inhibiting virus binding to cell membranes. The 
design of these inhibitors is challenging as many properties, for example, 
inhibitor size and functionalization with virus attachment factors, strongly 
influence the inhibition efficiency. Here, virus binding inhibitors are synthe-
sized, the size and functionalization of which are inspired by mucins, which 
are naturally occurring glycosylated proteins with high molecular weight 
(MDa range) and interact efficiently with various viruses. Hyperbranched 
polyglycerols (hPGs) with molecular weights ranging between 10 and 
2600 kDa are synthesized, thereby hitting the size of mucins and allowing 
for determining the impact of inhibitor size on the inhibition efficiency. The 
hPGs are functionalized with sialic acids and sulfates, as suggested from the 
structure of mucins, and their inhibition efficiency is determined by probing 
the inhibition of influenza A virus (IAV) binding to membranes using various 
methods. The largest, mucin-sized inhibitor shows potent inhibition at pm 
concentrations, while the inhibition efficiency decreases with decreasing the 
molecular weight. Interestingly, the concentration-dependent IAV inhibition 
shows a biphasic behavior, which is attributed to differences in the binding 
affinity of the inhibitors to the two IAV envelope proteins, neuraminidase, and 
hemagglutinin.
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thereby generating a multivalent interaction to the cell mem-
brane.[8] This first step in the infection cycle of cells can be 
inhibited by addition of multivalent binding inhibitors.[5,9]
The design of multivalent virus binding inhibitors is compli-
cated by the fact that many properties, such as inhibitor size and 
functionalization with virus attachment factors, have a strong 
impact on the inhibition efficiency,[10] making the process of 
finding inhibitor designs with high inhibition efficiency a time-
consuming matter. Nevertheless, the concept of using multiva-
lent interactions to hinder binding of infectious agents (viruses 
and bacteria) to cells is already implemented in nature by the bio-
logical hydrogel mucus, which covers almost all epithelia cells.[11] 
It forms the first defense barrier against viruses and bacteria by 
capturing such infectious agents before they are able to reach 
to the cell surface.[12] Mucus is formed by dynamic cross-linking 
of mucins, which are highly glycosylated proteins having mole-
cular weights ranging between 0.1 and few MDa and bind with 
high specificity and selectivity to viruses while allowing other 
species (e.g., nutrients) to pass the hydrogel.[11,13] As mucins are 
effective binders of various virus species, our study aims to syn-
thesize virus binding inhibitors, the size and functionalization 
of which is inspired by mucins, thereby allowing for potent and 
potentially broad band inhibition of virus binding.
In particular, we aim to generate multivalent virus binding 
inhibitors reaching molecular weights on the MDa scale, which 
is a value being in the middle of the weight range reported for 
mucins.[13] Besides mimicking the size of mucins, such large 
values are further motivated by the observation that the size of 
a binding inhibitor has a strong impact on its efficiency to bind 
to viruses,[10] which led to the suggestion that the optimal size 
of a virus binding inhibitor is approximately one third of the 
size of the virus to be inhibited. As many viruses are within 
the size range of 30–200  nm, the size of the virus inhibitor 
should therefore be on the order of a few tens of nanometers, 
corresponding to polymer scaffolds with a molecular weight 
hitting the MDa scale. Besides size, the functionalization of 
the inhibitor is also known to be an important determinant for 
the strength of the virus-inhibitor interaction. Mucins present 
a high amount of terminal sialic acid and sulfate moieties,[12] 
which are known to play a role in the binding of various viruses. 
This motivates to functionalize the virus binding inhibitor with 
sialic acid and sulfate groups (at degrees of functionalization 
comparable to mucins) to ensure efficient binding to viruses, 
thereby offering the perspective to provide broad band virus 
binding inhibition activity.
The performance of the synthesized, mucin-inspired virus 
binding (MuVib) inhibitors is investigated by probing the 
binding inhibition of a H3N2 influenza A virus (IAV) strain 
using various assays, including a new binding assay based on 
total internal fluorescence (TIRF) microscopy. MuVib inhibitors 
with molecular weights ranging between 10 and 2600 kDa are 
synthesized, which allows to probe the inhibition efficiency as a 
function of inhibitor size.
2. Results and Discussion
The aim of this study is to synthesize virus binding inhibitors, 
the size and functionalization of which have been motivated 
by mucins. With respect to size, this aim requires to synthe-
size macromolecules having molecular weights on the MDa 
scale, which can then serve as scaffold for further function-
alization with virus attachment factors. Recent studies have 
demonstrated the synthesis of virus inhibitors hitting the MDa 
range, which were based on polyacrylamide, polyamidoamine, 
polyethylene imine or copolymers of them,[14] but showed only 
little biocompatibility due to their positive charges. In order 
to generate a high molecular weight (MDa-sized) multivalent 
virus binding inhibitor, we therefore decided to use hyper-
branched polyglycerols (hPG), which are known to be highly 
biocompatible and the synthesis of single hPG molecules with 
molecular weights of several 100 kDa has recently been demon-
strated.[15,16] The strategy for the synthesis of MDa-sized hPG 
molecules for use as mucin-inspired virus binding (MuVib) 
inhibitor is shown in Figure  1a. In addition to this inhibitor, 
hPGs with lower molecular weights (ranging between 10 and 
500 kDa) have been synthesized, which allows for investigating 
the effect of the inhibitor size on the inhibitor efficiency as sug-
gested in a recent work by Vonnemann et  al.[10] While single 
hPG molecules up to 600  kDa can be synthesized in a single 
step,[17] the synthesis of the 2600 kDa hPG molecules required 
an additional step, in which 600 kDa hPGs served as macroini-
tiator for a further polymerization (Figure  1a) to generate a 
mucin-sized polymer.[16] This approach yielded 4 different hPG 
scaffolds with molecular weights of 10, 100, 500, and 2600 kDa 
(Table  1). DLS measurements yielded hydrodynamic diameter 
of ≈6  nm (10  kDa), 9  nm (100  kDa), 13  nm (500  kDa), and 
29 nm (2600 kDa), respectively.
Besides size, the functionalization of a polymer scaffold sur-
face with chemical groups is also an important parameter for 
its efficiency to serve as virus inhibitor, as it determines the 
amount and strength of interactions formed between a virus 
and the inhibitor.[7] In this work, the hPG-based inhibitors were 
functionalized with sialic acids (SAs) and sulfate groups, which 
is motivated by the fact that many terminal glycans in mucins 
terminate either with a sialic acid (SA) or a sulfate group.[13] 
Furthermore, both groups are known attachment factors for 
various viruses:[18] SAs are, for example, involved in the attach-
ment of influenza virus and many corona virus strains,[19,20] 
while viruses such as the vesicular stomatitis virus or herpes 
simplex virus bind to sulfated glycosaminoglycans.[21,22] As 
these two chemical groups already enable interaction with 
various virus species, we simplified the complex structure of 
mucins by regarding only these two terminal functional groups 
and thus by functionalizing the hPG scaffolds with SAs and 
sulfate residues as shown in Figure 1b.
Various values for the content of SA and sulfate groups in 
mucins have been reported in the literature, typically ranging 
between 4–20  wt% for sialic acid and 1.2–11.9  wt% for sul-
fates.[23,24] In this study, 5 mol% of the hydroxyl groups were 
substituted with SA and sulfate moieties (Figure  1b), respec-
tively, which resulted in 15 wt% SA and 5 wt% sulfate (Table 1), 
being close to the middle of the ranges reported for mucins. 
In addition, for the 2600  kDa inhibitor two control polymers 
were prepared, carrying only one of the two moieties. All func-
tionalized inhibitors show a negative zeta potential ranging 
from −22 to −27  mV (Table  1), which is caused by the incor-
poration the negatively charged sulfate and SA moieties. Both, 
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unfunctionalized and functionalized hPG polymers are highly 
water soluble. Furthermore, a predominantly spherical mor-
phology of the MuVib inhibitor was verified using cryo-electron 
microscopy (see Figure S1, Supporting Information).
In a next step, we assessed the applicability of the synthe-
sized inhibitors to hinder binding of viruses to cell membranes. 
These investigations were done using influenza A virus (IAV), 
being a highly important representative of the viruses that bind 
to cells via SAs. In particular, we employed the IAV strain X31 
(H3N2), which is often used for assessing the efficiency of IAV 
binding inhibition and thus allows for comparing the measured 
inhibition efficiency with literature values.[25–27] Interestingly, 
two membrane proteins are involved in this binding process of 
all IAVs: Hemagglutinin (HA) and neuraminidase (NA). Both 
proteins are able to interact with SAs, but while HA is known 
to promote IAV attachment to the cell membrane, NA is known 
to possess SA cleavage activity and is therefore believed to 
promote IAV egress (after the virus replication cycle has been 
completed).[28–30] The interplay between HA and NA is known 
to be important for completion of the virus life cycle and started 
Figure 1. Synthesis of mucin-inspired virus binding (MuVib) inhibitors based on high-molecular weight hPG. a) Polymerization of the MDa hPG in 
two steps i) potassium methoxide in dry 1,4 dioxane at 95 °C and glycidol addition (0.5 mL h−1), ii) potassium hydride in dry DMF at 95 °C and glycidol 
addition (0.9 mL h−1). b) Functionalization of the MDa hPG, all reactions were carried out in dry DMF under argon atmosphere, iii) mesylation with 
mesyl chloride and triethylamine at room temperature for 20 h, iv) azidation using sodium azide at 80 °C for 20 h, v) sulfation with sulfur trioxide 
pyridine complex at 60 °C for 20 h, vi) copper-catalyzed alkyne-azide cycloaddition using copper sulfate pentahydrate, sodium ascorbate at 50 °C for 
20 h, vii) deprotection with sodium hydroxide at room temperature for 2 h.
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to attract the focus of recent research.[31] According to Harris 
et  al.[32] there are ≈300 copies of HA compared to 50 copies 
of NA in the membrane of the influenza A virus strain X31. 
To prevent NA-mediated cleavage of SAs at our synthesized 
binding inhibitor, a thioether bond was used to link the sialic 
acid to the polymer scaffold, which cannot be cleaved by NA.
In this study, the inhibitor performance was first investigated 
using the hemagglutination inhibition (HAI) assay (Figure S2, 
Supporting Information), which takes advantage of the feature 
that red blood cells become crosslinked upon interaction with 
IAVs (called hemagglutination).[33] By addition of virus binding 
inhibitors, the interaction between the virus and the mem-
branes of red blood cells can be inhibited and the lowest inhib-
itor concentration at which no agglutination occurs anymore 
is defined as (HAI assay-derived) inhibition constant ki. This 
assay is a well-established means for determining the amount 
of inhibitor (concentration) that has to be added in order to 
efficiently inhibit IAV binding to RBC membranes.[34] For the 
10 and 100 kDa inhibitors we observed ki values in the low µm 
range (Table 2), whereas the 500 kDa inhibitor approached the 
nm range and the most potent inhibition was exhibited by the 
2600  kDa MuVib inhibitor (31 pm; 0.1  µg mL−1), irrespective 
if this hPG was functionalized with SA and SO4 or SA alone. 
The inhibitors lacking SA (i.e., the sulfated hPGs) showed no 
notable inhibition.
Although the HAI assay is often used to assess the inhibi-
tory potential of compounds, it does not allow to directly probe 
the interaction of IAVs with their attachment factors or how 
this interaction is altered by addition of inhibitors. In order to 
obtain such information, we extended a recently introduced 
virus-membrane binding assay based on total internal reflec-
tion fluorescence (TIRF) microscopy (Figure  2).[35] In this 
assay, a supported lipid bilayer (SLB), which is supplemented 
with the attachment factor of the virus of interest, is formed 
at a glass interface and the (transient) binding of fluorescently 
labeled viruses to the SLB is monitored using TIRF microscopy 
(Figure 2a). By choosing TIRF illumination, the excitation light 
hits the SLB-glass interface at the critical angle of total internal 
reflection, which generates an evanescent wave with a pen-
etration depth of ≈100–150 nm,[36] so that fluorescence is only 
excited in very close vicinity of the SLB. Hence, to resolve fluo-
rescently labeled viruses for an appreciable time period in TIRF 
microscopy, they have to be bound to the SLB, while unbound 
viruses are not visible.
For probing the IAV-SA interaction, a SLB based of POPC 
(96.2  wt%, 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine) and 
DSPE-PEG2k (3.8  wt.%, 1 mol%, 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] 
(sodium salt)) was supplemented with the ganglioside GD1a 
(2.5 wt%, 1 mol%), which presents SAs and thus provides the 
IAV attachment factor for the interaction studies. Although 
“human” IAV strains, such as X31 (H3N2), are known to prefer 
α-2,6-linked over α-2,3-linked SAs,[37] it has been shown that the 
corresponding difference in binding affinity is only minor (with 
HA-SA dissociation constants of Kd ≈ 2 and 3 mm for α-2,6 and 
α-2,3 linkage, respectively).[38] Despite the fact that GD1a pre-
sents α-2,3-linked SAs, its use in IAV-SA interaction studies is 
therefore justified and is, for example, in line with the fact that 
HAI assays probing X31 binding inhibition have been done in 
the past with RBCs presenting any of the two linkages.[39,40]
In order to image the viruses, the envelope of the IAVs was 
labeled with the dye rhodamine octadecyl and TIRF microscopy 
was used to follow IAV attachment to/release from the SA-con-
taining SLBs (Figure 2a). Single particle tracking (SPT) applied 
to the resulting TIRF microscopy videos allowed for tracking 
the motion of single viruses interacting with the SLB with high 
spatial accuracy (<15  nm) and subsequent application of the 
equilibrium fluctuation analysis (EFA)[41,42] yielded informa-
tion on the rate of IAV attachment to the SLB, the IAV diffu-
sion coefficient (which is a qualitative measure for the average 
Table 2. Inhibitor performance in comparison of HAI and TIRF 
measurements.
HAI ki TIRF IC50
[mol L−1] [µg mL−1] [mol L−1] [µg mL−1]
hPG10-SA-SO4 82 × 10−6 1214 2 × 10−6 30
hPG100-SA-SO4 5 × 10−6 685 0.6 × 10−6 82
hPG500-SA-SO4 50 × 10−9 35 0.4 × 10−6 279
hPG2600-SA-SO4 31 × 10−12 0.1 30 × 10−12 0.1
hPG2600-SA 31 × 10−12 0.1 3 × 10−12 0.01
hPG2600-SO4 no inh. no inh. no inh. no inh.
Table 1. Properties of synthesized virus binding inhibitors based on hPG.
da) ζ-pot.b) SO4c) SAc) nsulfated) nSAd)
[nm] [mV] [mol%] [wt%] [mol%] [wt%] [–] [–]
hPG10-SA-SO4 4.9 ± 4.2 −26.3 ± 0.9 7.2 6.2 7.0 19.3 7 7
hPG100-SA-SO4 12.0 ± 7.2 −22.4 ± 1.0 5.0 4.7 5.5 16.5 68 75
hPG500-SA-SO4 16.3 ± 9.7 −24.3 ± 0.8 3.9 3.7 5.7 17.1 268 392
hPG2600-SA-SO4 28.1 ± 17.1 −26.8 ± 1.1 5.0 4.7 5.6 16.7 1724 1931
hPG2600-SA 29.2 ± 15.3 −23.4 ± 0.5 – – 5.6 17.7 – 1931
hPG2600-SO4 20.8 ± 11.4 −17.1 ± 0.9 4.3 5.3 – – 1482 –
hPG2600 28.9 ± 14.9 9.5 ± 0.5 – – – – – –
a)Hydrodynamic diameter obtained by DLS at sample concentration of 1 mg mL−1 in PBS (10 mm, pH 7.4); b)Zeta-potential measurement in 10  mm phosphate buffer 
(pH 7.4); c)amount of converted hydroxyl groups in percent, determined by elemental analysis, degree of sialic acid based on fully conversion of azide moieties; d)calculated 
number of sialic acid and sulfate per polymer based on Mn.
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number of attachment factors bound by the tracked IAV), and 
the IAV residence time distribution as described previously.[35]
As the inhibitors were designed to prevent IAV binding to 
membranes, it is straightforward to assess their inhibition effi-
ciency by quantifying the change of the rate of IAV attachment 
to the SA-presenting SLB as function of the inhibitor concentra-
tion (Figure 2b). According to the EFA procedure,[41,42] this rate 
is extracted by calculating, for each recorded TIRF movie sepa-
rately, the total number of IAVs that have been newly bound to 
the SLB since the beginning of the TIRF movie. Under equi-
librium conditions (i.e., if SLB-bound and solution-dissolved 
viruses are in thermodynamic equilibrium) this number, the 
so-called cumulative number of newly arising viruses, increases 
linearly with measurement time, and the slope of this function 
Figure 2. Experimental setup used to study IAV X31 binding to sialic acids (SAs) and the modification of this interaction upon addition of hPG inhibi-
tors. a) Supported lipid bilayers (SLBs) containing the sialic acid-presenting ganglioside GD1a were used as artificial cell membranes. Fluorescently 
labeled IAVs (R18 dye incorporated in the virus envelope) bind to sialic acids exposed by the SLB, a process which is followed by TIRF imaging (always 
performed at room temperature; 20 °C). b) The cumulative number of newly arriving IAVs, as calculated using the EFA procedure, increases linearly 
with time. The slope of these traces is proportional to the rate of IAV attachment to the SA-containing SLB and allows for determining IAV binding 
inhibition upon addition of hPG inhibitors. The plot shows a representative example using the inhibitor hPG10-SA-SO4.
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corresponds to the IAV attachment rate for the area probed.[41,42] 
Addition of the inhibitors changed the slope of the cumulative 
number of newly arising IAVs, which indicates a change of the 
rate of IAV attachment to the SLB caused by the presence of 
the inhibitors (Figure 2b). Strong inhibition of IAV binding is 
reflected by a strong decrease in the IAV attachment rate, so 
that the change in the IAV attachment rate (with respect to its 
value in absence of any inhibitor) is indicative for the inhibition 
efficiency.[22] Hence, in the following all IAV attachment rates 
will be normalized by the value in absence of any inhibitor, 
which is denoted as relative on-rate in this work.
As expected for binding inhibitors, all SA-presenting hPGs 
showed a decrease in the relative on-rate for a sufficiently large 
inhibitor concentration (Figure  3). Fitting a Langmuir-type 
inhibition curve to the relative on-rate in this concentration 
range allowed for determining the inhibitor concentration, at 
which the IAV binding rate to the SLB has been reduced by 
50% (the so-called IC50 value; Table 2). While the 10 to 500 kDa 
Figure 3. Change in IAV attachment rates upon hPG inhibitor (10, 100, 500, 2600 kDa) addition. Shown is the relative on-rate, which was calculated by 
normalizing the IAV attachment rate at a given hPG inhibitor concentration by the IAV attachment rate in absence of the inhibitor (i.e., at 0 m inhibitor 
concentration). Dashed lines are fixed to a relative on-rate value of one and thus show, if the rate of IAV attachment increases (>1) or decreases (<1) 
upon inhibitor addition. Surprisingly, both cases are observed for all SA-presenting inhibitors (except for the 100 kDa compound), generating a biphasic 
behavior in IAV binding inhibitor (see main text for details). Solid lines are fits of a Langmuir-type inhibition model to the data, allowing to determine 
the IC50 value of the inhibitors. Symbols indicate average values ± standard deviation of at least five measurements.
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hPG inhibitors showed IC50 values in the µm  molar range, the 
2600  kDa hPG inhibitors reached pm values. This impressive 
value is not only due to the high molecular weight of these 
large inhibitors, but also by an improved inhibition potential 
as indicated when comparing the IC50 values expressed in mass 
concentrations (Table 2); compared to the smaller inhibitors, a 
virus inhibition is achieved for the 2600  kDa hPGs at a three 
order of magnitudes lower mass concentration, which is indica-
tive for a multivalency-based enhancement of the inhibition. 
In addition, both SA-functionalized 2600  kDa hPGs showed 
comparable inhibition efficiency, that is, hPGs with SA and 
sulfate functionalization is not notably more effective than the 
inhibitor with just SA, while the one lacking SA but carrying 
sulfates did not show any IAV inhibition. Both observations are 
expected, as IAVs bind with much higher affinity to sialic acids 
than to sulfates, so that the interaction is dominated by sialic 
acids for the SA-containing inhibitors and negligible (for the 
inhibitor concentrations investigated) if only sulfates are pre-
sent on the inhibitor.
As inhibition is only observed for inhibitors presenting 
SAs (which are known to be the IAV attachment factor) and as 
SA-presenting inhibitors (see Table 1) as well as SA-presenting 
bilayers are negatively charged,[43] IAV inhibition must be due 
to binding of the hPG-based inhibitors to the viruses. This con-
clusion is in line with the observations of related SA-presenting 
inhibitors and the measurement of size distributions of IAVs in 
presence and absence of the inhibitor (Figure S3, Supporting 
Information).[25]
In contrast, the non-functionalized MDa hPG also showed 
inhibition in the TIRF-based assay with an apparent IC50 value 
of ≈1000 pm, while no inhibition was observed in the HAI assay. 
We attribute this behavior to the slightly positive zeta poten-
tial (Table S1, Supporting Information) of this polymer, which 
promotes its binding to negatively charged sialic acid groups 
presented by the SLB and thus blocks the interaction between 
IAVs and the SLB by steric depletion of the attachment factors. 
This view is confirmed by the lack of any inhibition potential 
of hPG2600-SO4, which possesses, as all functionalized hPGs, a 
negative surface charge and is therefore not able to bind to the 
negatively charged SLB. A reason for its positive zeta potential 
of the non-functionalized MDa hPG could be the incorpora-
tion of salt ions although the polymer was excessively dialyzed 
against water. A treatment of the polymer solution with cation 
exchanger before the measurement of the zeta potential did not 
change the slightly positive zeta potential result. All functional-
ized hPGs showed the expected zeta potential, which verifies 
the measurement principle.
Nevertheless, for all SA-presenting inhibitors the results on 
IAV binding inhibition obtained using the HAI- or TIRF-based 
assays are qualitatively in good agreement (Table  2), although 
the TIRF-based assay reports in general slightly smaller IC50 
values than the HAI-assay. Both assays show that the IC50 
values generally decrease with increasing inhibitor size, that is, 
that the inhibitors become more potent for increasing size of 
its scaffold. This trend is in fact expected based on the theo-
retical considerations of Vonnemann et al.,[10] who show based 
on geometrical considerations that an optimal size for binding 
inhibitors exists. These considerations show that increasing the 
inhibitor size also increases the contact area between inhibitor 
and virus and thus the virus-inhibitor interaction. Neverthe-
less, as the inhibitor mass also scales with the third power of 
the inhibitor size, this increase in inhibitor size also increases 
the applied mass concentration of the inhibitor, which partially 
cancels the enhancement caused by the increase in binding 
strength. Hence, there exists an optimum inhibitor size at 
which the lowest (total) mass of inhibitor is required for inhi-
bition and which is, according to Vonnemann et al.[10] approx-
imately one third of the size of the virus to be inhibited. As 
IAV X31 typically shows spatial extensions ranging between 
80 and 120 nm, an optimum in binding inhibition is expected 
for inhibitor diameters on the order of 30  nm, which is real-
ized by the MuVib inhibitor (hPG2600-SA-SO4, Table 1). In this 
context, the decrease of the IC50 value with increasing inhibitor 
size qualitatively matches to the predictions of Vonnemann 
et al.[10] A test, if the 2600 kDa MuVib inhibitor indeed achieves 
optimum inhibition efficiencies was, however, not possible, as 
this would have required to synthesize notably larger hPG scaf-
folds, which was not achievable in this study. A complementary 
approach to achieve related inhibitors with larger sizes is nano-
precipitation, in which smaller hPGs are crosslinked to form 
nanogels. For example, Bhatia et. al. recently introduced hPG-
based nanogel inhibitors with sizes of ≈250  nm and achieved 
IC50 values of about 30 µg mL−1.[25] This performance is two to 
three magnitudes lower than the one of the 2600  kDa MuVib 
inhibitor and indicates that the optimum inhibitor size for IAV 
binding inhibition is in between of 30 and 250 nm.
Nevertheless, while the HAI assay provides a rather binary 
readout (i.e., if the inhibitor concentration is sufficient to 
inhibit agglutination of red blood cells),[33] the changes in the 
IAV attachment rate measured by TIRF showed biphasic pro-
gression: Starting at small inhibitor concentrations (<<IC50), 
the attachment rates first increased with increasing inhibitor 
concentration, followed by a saturation and a strong decrease at 
large inhibitor concentrations (≈IC50). This surprising behavior 
indicated that the SA-functionalized hPG inhibitors promoted 
IAV attachment at relatively low inhibitor concentrations, while 
IAV binding inhibition was observed for sufficiently large inhib-
itor concentrations. The first phase (increase in IAV attachment 
rate) is not resolvable in the HAI-assay, as the IAV concentra-
tion is chosen such that IAV-induced agglutination is observed 
in absence of the inhibitor. This means that an increase in the 
IAV attachment rate to the cell membranes is not resolved by 
HAI, as in absence of inhibitors the IAV attachment rate is 
already sufficiently large to achieve agglutination.
This biphasic behavior, which was observed for all inhibi-
tors except for hPG100-SA-SO4 and which first increases the 
IAV binding rate to membranes at low inhibitor concentrations 
until a decrease is observed at large concentrations, was unex-
pected. Nevertheless, the observed increase in IAV attachment 
rate resembles changes to the IAV binding properties observed 
upon application of neuraminidase inhibitors.[35] Hence, the 
biphasic behavior suggests that at relatively low concentra-
tions the inhibitors bind first to the NA and therefore act as NA 
inhibitors, while binding to HA and thus binding inhibition 
requires higher inhibitor concentrations. This interpretation 
is consistent with measurements on the affinity of the enve-
lope proteins to sialosides,[44,45] showing that the dissociation 
constant Kd of the NA-SA interaction is 3 order of magnitude 
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smaller than the one of the HA–SA interaction (≈µm vs. ≈mm, 
respectively) and supporting the hypothesis that also the inhibi-
tors exhibit higher affinity (lower Kd value) towards NA than 
HA. Furthermore, evidence is accumulating that NA also con-
tributes to the process of IAV binding to membranes.[33,46]
If the hypothesis is correct that the inhibitors bind preferen-
tially to NA at relatively low inhibitor concentrations and to HA 
at sufficiently large ones, one would expect to see inhibitor con-
centration-dependent changes of the IAV off-rate and valency 
distribution, as both IAV binding properties strongly depend on 
the functional balance between HA and NA.[35] In order to test 
this hypothesis, we extracted IAV off-rate and valency distribu-
tions from the TIRF measurements as recently described.[35] 
In brief, here we make use of the fact that the diffusion coef-
ficient of SLB-bound IAVs, D, decreases with increasing valency 
(=number of bound GD1a gangliosides), so that the changes to 
the IAV valency distribution also induce changes to the distri-
bution of IAV diffusion coefficients. Although the exact rela-
tionship connecting IAV valency and diffusion coefficient has 
not yet been resolved, all theoretical models indicate that both 
properties are connected by a monotonously decreasing func-
tion, that is, large values of the diffusion coefficient correspond 
to a small value of the average valency and vice versa.[47] Fur-
thermore, the measurement of the IAV diffusion coefficient 
also allows to deconvolute the IAV residence time distribu-
tion from valency effects, yielding valency-resolved off-rate 
distributions.[35]
In absence of any inhibitor (open circles, Figure  4a), the 
observed off-rate distribution is dominated by a decrease for 
increasing apparent average valency D−1, but also shows a peak 
structure, leading to elevated off-rates at intermediate average 
valencies (D−1  ≈ 8 s µm−2).The presence of a peak structure 
matches to previous observations,[35] in which it is shown that 
this structure is caused by the opposing functionalities of HA 
and NA and vanishes upon application of NA inhibitors such 
as zanamivir. Furthermore, the addition of zanamivir also 
increased the rate of IAV attachment and both effects together 
yielded a strong increase in the number of bound IAVs. Inter-
estingly, exactly the same behavior is observed here at rela-
tively low inhibitor concentrations, at which the relative IAV 
on-rate increases (Figure 3) and the IAV off-rate decreases with 
increasing inhibitor concentration (open triangles and squares, 
Figure  4a). Hence, at relatively low concentrations, the inhibi-
tors behave like a NA inhibitor with respect to the induced 
changes in IAV attachment and off-rate distribution.
Additional evidence is provided by the diffusion coefficient 
distributions (Figure  4b), which showed a shift from large to 
small values upon addition of small amounts of the inhib-
itor (<<IC50) and a shift from small to large diffusion coef-
ficient values upon addition of large amounts of the inhibitor 
(>>IC50). As the diffusion coefficient D is indicative for the 
average valency of the IAV-SA interaction, these changes indi-
cate that the addition of inhibitors modifies the IAV valency dis-
tribution. In particular, the shift from large to small D-values 
observed for inhibitor concentrations below IC50 indicates an 
increase of the average binding valency (“NA-like inhibition”), 
while the opposite behavior is observed above IC50 and thus 
indicates a decrease in average binding valency (“HA inhibi-
tion”). There is, however, a lower limit for the valency, below 
which the interaction of the IAV to the membrane becomes too 
small to maintain IAV binding to the membrane. This limit is 
reached for D-values exceeding ≈1 µm² s−1, so that the D-distri-
butions exhibit an edge at ≈1 µm² s−1 and, in connection with 
the transfer of events from small to large D-values, a peak-like 
structure, which raises with increasing inhibitor concentration 
added.
Figure 4. a) Changes of the IAV off-rate and b) diffusion coefficient distribution upon addition of the hPG2600-SA-SO4 MuVib inhibitor. The biphasic 
binding behavior is also observed in these distribution, as addition of small amounts of the inhibitor (≤20 pm) leads to a decrease in the off-rate distri-
bution and a shift of the diffusion coefficient distribution from large to small values (indicating an increase in average binding valency), while addition 
of larger amounts of the inhibitor (>20 pm) restores the off-rate distribution and shifts the diffusion coefficient distribution from small to large values 
(indicating an decrease in average binding valency).
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Nevertheless, in order to probe, if the phenomenon of 
increased IAV attachment rates at small inhibitor concentra-
tions (<<IC50) can also be observed for native cell plasma 
membranes, we further investigated the IAV binding to 
MDCK-II cells, which are known to expose α-2,6-linked and 
α-2,3-linked SAs and are an established cell line for investi-
gating IAV binding to and infection of cells.[48] Here, labelled 
IAVs were mixed with different concentration of the inhibitor 
hPG2600-SA-SO4 at room temperature for 45  min. Afterwards, 
the virus-inhibitor mixture was incubated with MDCK-II cells 
for 2 h on ice. Non-bound IAVs were removed by washing twice 
with PBS buffer, while bound IAVs remained at the cell sur-
face. Using confocal laser scanning microscopy Z-wide images 
of the cell layer were taken and stacked to visualize all viruses at 
the cell surface, followed by quantifying the number of bound 
viruses using ImageJ.[49] The number of MDCK-II cell-bound 
IAVs (Figure 5) showed the same dependence of the inhibitor 
concentration as the relative on-rate determined using TIRF 
microscopy (Figure 3), verifying an increased IAV attachment at 
low concentrations and a decrease in IAV attachment at higher 
concentrations. The sulfated derivative (hPG2600-SO4) was used 
as negative control and showed no impact on the IAV binding. 
Hence, the biphasic change in the IAV binding behavior upon 
inhibitor addition is observed for IAVs interacting with attach-
ment factor-equipped SLBs as well as with cell membranes, 
which further supports our view that these inhibitors behave 
as NA-like inhibitors at low inhibitor concentrations and as HA 
inhibitors at high concentrations. Furthermore, as MDCK-II 
cells present α-2,6-linked as well as α-2,3-linked SAs, obtaining 
the same inhibition curve as in the TIRF assay post-validates 
that GD1a is a suitable attachment factor for probing the inter-
actions between IAV X31 and GD1a.
3. Conclusions
In this study, hyperbranched polyglycerol (hPG)-based virus 
binding inhibitors have been synthesized, the size and func-
tionalization of which have been inspired from mucins. The 
resulting mucin-inspired virus binding (MuVib) inhibitor was 
based on a 2.6 MDa hPG core that was functionalized with 
sialic acids and sulfate groups (5 mol% of the hPGs OH groups, 
respectively). In addition, hPG-based inhibitors having the same 
functionalization but lower molecular weights (ranging between 
10 and 2600  kDa) were synthesized as well, which allowed to 
probe the impact of the inhibitor size on its inhibition efficiency. 
This efficiency of the synthesized compounds in inhibiting the 
binding of a common respiratory virus, a H3N2 influenza A 
virus (IAV), was assessed using a cell binding and the hemag-
glutination inhibition assay, both of which provide informa-
tion about the minimum inhibitor concentration that needed 
to inhibit IAV binding to membranes. Furthermore, a recently 
developed TIRF-based assay was employed to quantify, how 
inhibitor addition modified the multivalent interaction arising 
between IAVs and their native attachment factor, sialic acids.
Surprisingly, the inhibition of IAV binding to membranes 
showed a biphasic behavior for increasing inhibitor concentra-
tions: At relatively low inhibitor concentrations, the IAV binding 
Figure 5. Inhibition of IAV X31 binding to MDCK II cells upon addition of the hPG2600-SA-SO4 MuVib inhibitor (green symbols) and of the negative 
control hPG2600-SO4 (yellow symbol). The cell-based assay also shows a biphasic change of IAV binding inhibition as observed in the TIRF-based binding 
assay. IAVs were labeled with DiO (green structures in the cell images), while the MDCK II cells were labeled using Hoechst 33 258 (blue structures). 
Symbols indicate average values ± standard deviation of four measurements. Dashed lines are to guide the eye.
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first increased with increasing inhibitor concentrations, fol-
lowed by a second regime at higher inhibitor concentrations, 
at which the expected decrease in IAV binding was observed 
for increasing inhibitor concentrations. The results of the 
TIRF-based assay and the cell binding assay indicate that the 
inhibitors bind at low inhibitor concentrations preferentially to 
the IAV envelope protein neuraminidase (NA), leading to an 
enhancement of the IAV binding to lipid membranes, while at 
larger inhibitor concentrations, it binds additionally to another 
IAV envelope protein, hemagglutinin (HA), causing IAV binding 
inhibition. Potent inhibition of IAV binding (HA inhibition) by 
the 2600  kDa MuVib inhibitor is observed in all these assays 
already at pm concentrations, while decreasing the molecular 
weight of the inhibitors decreased their inhibition efficiency 
(increase in their IC50 value), which is in qualitative agreement 
with the prediction by a recent study of Vonnemann et al.[10]
4. Experimental Section
Synthesis of High-Molecular Weight hPG: The synthesis of the MDa 
hPG was perfomed in two steps,[16] as previous investigations showed 
that using one step approaches the molecular weight of hPGs can be 
increased to only 800–900 kDa.[17,50] This limitation has been attributed 
in the past to the decrease in the concentration of active alkoxide 
units on polyglycerol, which are key elements to chain/branching and 
propagation of the hPG systems.[51]
First, a macroinitiator was synthesized in a heterogenous reaction 
mixture in dioxane. Dry trimethylolpropane (120 mg, 0.89 mmol, 1.0 eq.) 
was partially deprotonated (30% OH) with potassium methoxide 
(67 µL, 0.27 mmol, 0.3 equiv., 25% in methanol) in argon atmosphere 
at 60 °C for 30 min. After the addition of 24 mL dioxane (dry) the turbid 
mixture was heated to 100 °C. Glycidol (12 mL, 0.18 mol, 201 equiv.) was 
slowly added (0.5  mL h−1) via syringe pump into the reaction mixture. 
The polymer was purified by removing the dioxane, precipitation as 
methanolic solution in acetone and dialysis against water in regenerated 
cellulose membrane (10 kDa MWCO). The resulted hPG (Mn: 600 kDa, 
Đ 1.1) was obtained with a yield of 93.6 %.
In the second step, this hPG was used as macroinitiator to grow the 
polymer further. 2.5  g (0.034  mol, total OH groups) of the lyophilized 
polymer was dissolved in dry DMF (35 mL). The polymer was partially 
deprotonated with the addition of potassium hydride in oil (30  wt%) 
(80  µg, 272  µL, 2.0  µmol). The temperature was increased to 100  °C 
and glycidol (25  mL, 0.37  mol) were added with a rate of 0.9  mL h−1. 
After precipitation in acetone and dialysis against water in regenerated 
cellulose membrane (50 kDa MWCO) the resulted molecular weight was 
2.6 MDa with a Đ of 1.4.
Mesylation and Azidation: Both reactions were performed sequentially 
in one pot. 1300 mg hPG (2.6 MDa) (0.88 mol OH to be functionalized) 
was dissolved in dry DMF (18  mL). The mesylation was done with 
methanesulfonyl chloride (201  mg, 1.8mmol,  2.0 eq.) in the present of 
triethyl amine (306 µL, 2.2 mmol, 2.5 mol eq.) at room temperature for 
16 h. Afterwards the azidation was directly performed by the addition 
of sodium azide (456 mg, 7.0 mmol, 8 equiv.) at 80 °C for 20 h under 
argon atmosphere. Purification was done by dialysis against water 
(2 kDa MWCO, benzoylated). The product was analyzed by 1H NMR and 
elemental analysis to determine the amount of introduced azide groups 
(see Figure S5, Supporting Information).
Sulfation: The azidated hPG (400  mg, 0.27  mmol OH to be 
functionalized, 1.0 equiv.) was sulfated using sulfur trioxide pyridine 
complex (55.9 mg, 0.4 mmol, 1.3 equiv.) in dry DMF (12 mL) at 60  °C 
for 20 h under argon atmosphere. After the reaction time was over the 
pH value was increased to pH 10 by the addition of sodium hydroxide 
solution (0.3  mol L−1). The product was dialyzed against sodium 
hydroxide solution (0.3 mol L−1), 10 wt% NaCl and water. The yield of the 
sulfation was analyzed by elemental analysis. Further, a 1H NMR of the 
product was performed (see Figure S6, Supporting Information).
Click Protected Propagylated Sialic Acid by CuAAC: The sulfated 
polymer hPG2600-N3-SO4 (150  mg, 0.11  mmol OH to be functionalized, 
1.0 equiv.) was mixed with acetyl protected propagylated sialic acid 
(72.9  mg, 1.3  mmol, 1.2 equiv.) in DMF. Copper sulfate pentahydrate 
(11.1  mg, 0.04mmol,  0.4 equiv.) and sodium-l-ascorbate (88.3  mg, 
0.4 mmol, 4 equiv.) were dissolved separately in a small amount of water 
and combined afterwards. The solution was transferred to the polymer 
solution. The reaction was performed at 50  °C for 20   under argon 
atmosphere. Infrared spectroscopy indicated complete conversion by the 
disappearance of the azide band (2100 cm−1; see Figure S7, Supporting 
Information) within the resolution limit of the instrument (determined by 
multiple repetitions of the measurement and calculation of the standard 
error). Hence, it is reasonable to assume that the functional degree of 
conjugated sialic acid is almost the same as the initial degree of azidation 
(≈5–7 mol%). The pH value was increased to pH 10 with sodium 
hydroxide solution (2 mol L−1) to cleave the acetyl protection of the sialic 
acid within 2 h. EDTA disodium salt (14.0  mg, 0.04  mmol, 0.4 equiv.) 
was added to improve the removal of copper ions during dialysis against 
water. The purified polymer was analyzed by 1H  NMR (see Figure S9, 
Supporting Information) and elemental analysis.
The synthesized virus binding inhibitors were characterized in regard 
to size with dynamic light scattering (DLS) and in respect of surface 
charge by zeta potential measurements.
Dynamic Light Scattering: The hydrodynamic diameter was 
measured by dynamic light scattering at a concentration of 1 mg mL−1 
in PBS buffer using Zetasizer Nano series (λ = 532 nm) from Malvern 
Panalytical (Kassel, Germany). Disposable cuvettes (ZEN0040) from 
Brand (Wertheim, Germany) out of polystyrene were used. Before the 
measurement all samples were filtered through a 0.2  µm Minisart RC 
15 syringe filter from Satorius (Göttingen, Germany). Temperature 
equilibration was done for 1  min at 25  °C. The measurements were 
performed for ten scans each 15 s in back scattering mode (173°). The 
stated values result from at least three measurements.
Zeta-Potential: The surface charge was investigated by zeta-potential 
measurement with Zetasizer Nano series (λ  = 532  nm) using folded 
capillary zeta cells (DTS 1070) from Malvern Panalytical (Kassel, 
Germany). The sample concentration was 1 mg mL−1 in 10 mm phosphate 
buffer solution (0.411  g L−1 NA2HPO4, 0.178  g L−1 KH2PO4, pH 7.4). 
All samples were filtered through a 0.2 µm Minisart RC 15 syringe filter 
from Satorius (Göttingen, Germany). Five measurements with ten 
scans (each 15 s) were done to obtain the zeta potential based on the 
Smoluchowski model.
The virus binding performance was investigated by two independent 
methods: hemagglutination inhibition (HAI) assay and total internal 
reflection fluorescence (TIRF) microscopy.
Hemagglutination Inhibition Assay: The inhibitors were two-fold 
diluted with PBS in a v-shaped microtiter plate. Afterwards, 2 HA X31 
virus were transferred to each inhibitor dilution. After 30 min incubation 
time at room temperature 50  µL of 1% chicken RBC solution (Robert 
Koch-Institute, Berlin) was added to each well. Then, it was incubated 
for 60  min at room temperature before the read out was done. The 
lowest concentration where the sedimentation of red blood cells was 
still inhibited by hemagglutination represents the inhibitor constant ki 
(see Figure S2, Supporting Information).
Total Internal Reflection Fluorescent Microscopy: Single virus tracking 
was done on a supported lipid bilayer (SLB), which represents the 
cell surface. IAV bind in a multivalent fashion to incorporated GD1a 
gangliosides (1 mol%). Extruded vesicles out of POPC and 1 mol% GD1a 
were exposed in an aqueous solution (0.33 mg mL−1) on a cleaned glass, 
absorb, deform, and form a cohesive supported lipid bilayer by rupturing 
on the glass surface. Sialic acids on the GD1a are the natural target of 
IAVs. After 10  min excess vesicles were removed by washing with PBS 
buffer. Then, IAV solution with or without containing binding inhibitor 
was injected. Through excitation in TIRF mode, an evanescent light 
beam (white light + m-cherry filter) penetrates approximately 100  nm 
in the solution and reaches therefore just bound viruses (≈100 nm) on 
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the membrane. This ensures that rhodamine (R18) labeled viruses in the 
evanescent region get excited and emit light, non-bound labeled virus in 
the solution are not visible. Videos with 0.11 fps were taken to visualize 
the virus attachment, diffusion and detachment on the GD1a receptor 
containing SLB. The videos were analyzed by homemade MATLAB 
scripts using equilibrium fluctuation analysis (EFA).
IAV Binding to MDCK-II Cells: The cultured MDCK II cells were seeded 
in 8-well confocal slides and cultured for 1–2 days till confluency. 100 µL 
X31 solution (protein content: 0.36mg  mL−1, 1.1 × 1011 particles mL−1) 
was incubated with 2µL  of 20µm  DiO (in ethanol, D4929 in Merck, 
Darmstadt, Germany) for 30 min in dark. The free dyes were removed 
by spin column then. A mixture of 90  µL inhibitor (in PBS) and 10  µL 
labelled virus was added after 45 min at room temperature on the cell 
layer (culture medium was removed before by washing with PBS twice). 
After an incubation for 2 h on ice, non-binding viruses were removed 
by washing twice with PBS. The cell nucleus was labelled with Hoechst 
33 258 and the cells fixed with 4% paraformaldehyde. Finally, Z-wide 
images were taken with confocal laser scanning microscopy from the 
whole cell layer (30 images, step size 0.4 µm). The number of binding 
viruses was determined from the stacked images using ImageJ.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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